Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSV | O60911 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | PPIA | P62937 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071620 | 1.00 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL31443830 | 0.88 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL5440371 | 0.88 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL371728 | 0.86 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL31418722 | 0.86 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL143578 | 0.85 | MAPT (0.49) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL30152359 | 0.85 | MAPT (0.49) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL26621354 | 0.84 | MEN1 (0.52) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL7825518 | 0.84 | MEN1 (0.67) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL8161189 | 0.83 | MAPT (0.62) | MEN1KMT2AMAPTCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| CN-116874428-B | PNPO inhibitor with multiple myeloma resisting effect, and preparation method and application thereof | 南京中医药大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-119219606-A | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240368083-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2024-11-07 | — | — | US | disclosed |
| CN-113453681-B | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2024-10-11 | — | — | CN | disclosed |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| CN-116874428-A | PNPO inhibitor with multiple myeloma resisting effect, and preparation method and application thereof | 南京中医药大学 | 2023-10-13 | — | — | CN | disclosed |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2023-01-05 | — | — | US | disclosed |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3897635-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Celgene Corporation (US) | 2021-10-27 | — | — | EP | disclosed |
| US-6933299-B1 | Anilinoquinazolines as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | COCKERILL GEORGE S (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| US-6172077-B1 | TACHYKININ INHIBITORS; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIEMETICS; NEURALGIA, HEADACHES | MERCK SHARP & DOHME LTD. (GB) | 2001-01-09 | — | — | US | disclosed |
| EP-1019410-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2000-07-19 | — | — | EP | disclosed |
| US-6060469-A | Spiro-piperidine derivatives and their use as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-05-09 | — | — | US | disclosed |
| EP-0977758-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998049170-A1 | SPIRO-AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-05 | — | — | WO | disclosed |
| WO-1997019084-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | MEN1 2606/4885KMT2A 578/4885MAPT 3086/4885 |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MEN1 2606/4885KMT2A 578/4885MAPT 3086/4885 |
| US-20240368083-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | MEN1 2606/4885KMT2A 578/4885MAPT 3086/4885 |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MEN1 2824/4885KMT2A 582/4885MAPT 3309/4885 |
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | ABL1, ERBB2, ERBB4 | MEN1 3034/4885KMT2A 1442/4885MAPT 2249/4885 |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MEN1 2606/4885KMT2A 578/4885MAPT 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.